MacroGenics, Inc. (MGNX)

Price$3.91

Value ScoreB

Growth ScoreC

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)147.63%

Price vs S&P 500 (4W)30.34%

VGM Score65.57

Market Capitalization$248.53M

All Metrics

Book Value / Share (Quarterly)$0.33

P/TBV (Annual)3.28x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-0.53%

Cash Flow / Share (Quarterly)$-1.13

Price vs S&P 500 (YTD)134.70%

Gross Margin (TTM)74.45%

Net Profit Margin (TTM)-44.79%

EPS (TTM)$-1.11

10-Day Avg Trading Volume0.67M

EPS Excl Extra (TTM)$-1.11

Revenue Growth (5Y)7.34%

EPS (Annual)$-1.18

ROI (Annual)-59.42%

Gross Margin (Annual)75.91%

Net Profit Margin (5Y Avg)-89.99%

Cash / Share (Quarterly)$2.43

Revenue Growth QoQ (YoY)57.48%

ROA (Last FY)-29.05%

Revenue Growth TTM (YoY)1.97%

EBITD / Share (TTM)$-0.89

ROE (5Y Avg)-73.32%

Operating Margin (TTM)-40.53%

Cash Flow / Share (Annual)$-1.31

P/B Ratio11.72x

P/B Ratio (Quarterly)8.67x

Net Income / Employee (Annual)$-254,700

EV / Revenue (TTM)1.60x

Net Interest Coverage (TTM)-13.74x

ROA (TTM)-28.40%

EPS Growth QoQ (YoY)-70.10%

EV / EBITDA (TTM)4.55x

EPS Incl Extra (Annual)$-1.18

Current Ratio (Annual)5.10x

Quick Ratio (Quarterly)1.72x

3-Month Avg Trading Volume1.10M

52-Week Price Return169.66%

Revenue / Employee (TTM)$536,100

Tangible BV / Share (Quarterly)$3.13

P/S Ratio (Annual)1.66x

Asset Turnover (Annual)0.58x

52-Week High$4.64

Operating Margin (5Y Avg)-93.94%

EPS Excl Extra (Annual)$-1.18

CapEx CAGR (5Y)-20.19%

Tangible BV CAGR (5Y)-13.85%

26-Week Price Return155.56%

Quick Ratio (Annual)4.71x

13-Week Price Return82.71%

Total Debt / Equity (Annual)1.26x

Current Ratio (Quarterly)1.90x

Enterprise Value$250.73M

Revenue / Share Growth (5Y)3.41%

Asset Turnover (TTM)0.63x

Book Value / Share Growth (5Y)-30.10%

Revenue / Employee (Annual)$510,200

Inventory Turnover (Annual)9.10x

Pretax Margin (Annual)-50.36%

Cash / Share (Annual)$3.00

3-Month Return Std Dev122.63%

Gross Margin (5Y Avg)89.11%

Net Income / Employee (TTM)$-240,100

ROE (Last FY)-134.23%

Net Interest Coverage (Annual)-4.34x

EPS Basic Excl Extra (Annual)$-1.18

P/FCF (TTM)5.81x

Receivables Turnover (TTM)14.98x

EV / Free Cash Flow (TTM)3.52x

Total Debt / Equity (Quarterly)3.24x

EPS Incl Extra (TTM)$-1.11

Receivables Turnover (Annual)16.91x

ROI (TTM)-59.93%

P/S Ratio (TTM)1.58x

Pretax Margin (5Y Avg)-89.96%

Revenue / Share (Annual)$2.37

Tangible BV / Share (Annual)$2.30

Price vs S&P 500 (52W)145.29%

Year-to-Date Return142.86%

5-Day Price Return-5.56%

EPS Normalized (Annual)$-1.18

ROA (5Y Avg)-32.14%

Net Profit Margin (Annual)-49.91%

Month-to-Date Return-6.01%

Cash Flow / Share (TTM)$0.98

EBITD / Share (Annual)$-1.04

Operating Margin (Annual)-48.72%

LT Debt / Equity (Annual)1.26x

ROI (5Y Avg)-58.36%

LT Debt / Equity (Quarterly)3.24x

EPS Basic Excl Extra (TTM)$-1.11

P/TBV (Quarterly)2.40x

P/B Ratio (Annual)1.83x

Inventory Turnover (TTM)4.24x

Pretax Margin (TTM)-45.22%

Book Value / Share (Annual)$0.88

Price vs S&P 500 (13W)74.46%

Beta1.20x

P/FCF (Annual)39.70x

Revenue / Share (TTM)$2.48

ROE (TTM)-147.80%

52-Week Low$1.19

vGradeB

gGradeC

mGradeA

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.58est. -0.58

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.77

3.85

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
MGNXMacroGenics, Inc.	B	C	A	$3.91
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Macrogenics Inc. is a biotechnology company developing antibody-based therapeutics for cancer treatment. The company's marketed product, MARGENZA, is approved for metastatic HER2-positive breast cancer. Its pipeline includes three clinical-stage candidates: lorigerlimab, a bispecific DART targeting immune checkpoints PD-1 and CTLA-4; MGC026, targeting B7-H3; and MGC028, targeting ADAM9, each utilizing novel topoisomerase I inhibitor-based linker-payloads.